Pfizer market share

In 1993 and 1994 Merck, Lilly, and the then SmithKline Beecham all bought PBMs. In addition, Bristol-Myers Squibb had bid against Merck, and Pfizer and Johnson Johnson at one point considered purchasing benefits managers, too. Yet by 1999, Lilly and SmithKline had sold theirs at a loss, and Bristol-Myers, Johnson Johnson and Pfizer never got in. Merck alone seemed to be able to make its PBM, Merck-Medco Managed Care, work. By 2001, its market share was nearly 29 percent by 2002, it handled the prescriptions for 65 million people, or almost one-fourth of all Americans. 

The early 90 s saw 3 other companies launch competitor products with Pfizer s doramectin (Figure 11) establishing the highest market share. This gives better persistent anthelmintic activity than the early ivermectin products. 

Seven months after that, with the stock down in the 40s, Emma was still holding on to his Merck shares. But it wasn t based on faith so much any more. The price was just too low now—in fact, the entire market was too depressed—to do any selling. With Pfizer s new merger, I think Merck is going to get left behind rather quickly. I don t know what their strategy is. If I was going to buy anything in the pharmaceutical industry. I d buy Pfizer. ... 

---